CA3169117A1 - Cancer treatment methods - Google Patents

Cancer treatment methods Download PDF

Info

Publication number
CA3169117A1
CA3169117A1 CA3169117A CA3169117A CA3169117A1 CA 3169117 A1 CA3169117 A1 CA 3169117A1 CA 3169117 A CA3169117 A CA 3169117A CA 3169117 A CA3169117 A CA 3169117A CA 3169117 A1 CA3169117 A1 CA 3169117A1
Authority
CA
Canada
Prior art keywords
seq
amino acid
acid sequence
cancer
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3169117A
Other languages
English (en)
French (fr)
Inventor
Shelley Erin ACKERMAN
Michael N. ALONSO
David Dornan
Marcin L. KOWANETZ
Robert S. SIKORSKI
Steven A. Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bolt Biotherapeutics Inc
Original Assignee
Bolt Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bolt Biotherapeutics Inc filed Critical Bolt Biotherapeutics Inc
Publication of CA3169117A1 publication Critical patent/CA3169117A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3169117A 2020-02-25 2021-02-25 Cancer treatment methods Pending CA3169117A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062981355P 2020-02-25 2020-02-25
US62/981,355 2020-02-25
US202063105104P 2020-10-23 2020-10-23
US63/105,104 2020-10-23
PCT/US2021/019667 WO2021173832A1 (en) 2020-02-25 2021-02-25 Cancer treatment methods

Publications (1)

Publication Number Publication Date
CA3169117A1 true CA3169117A1 (en) 2021-09-02

Family

ID=75143716

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3169117A Pending CA3169117A1 (en) 2020-02-25 2021-02-25 Cancer treatment methods

Country Status (7)

Country Link
US (1) US20230165968A1 (https=)
EP (1) EP4110403A1 (https=)
JP (1) JP2023519807A (https=)
KR (1) KR20220145871A (https=)
AU (1) AU2021226570A1 (https=)
CA (1) CA3169117A1 (https=)
WO (1) WO2021173832A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109843327B (zh) 2016-07-07 2022-05-13 小利兰·斯坦福大学托管委员会 抗体佐剂缀合物
WO2020190725A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
WO2024130003A1 (en) 2022-12-15 2024-06-20 Bolt Biotherapeutics, Inc. Cancer combination treatment method
CA3221817A1 (en) * 2023-06-30 2025-06-13 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Combination therapies for the treatment of cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
JP2003531149A (ja) 2000-04-13 2003-10-21 ザ・ロツクフエラー・ユニバーシテイ 抗体由来の免疫応答の増強
WO2006073921A2 (en) 2004-12-30 2006-07-13 The Rockefeller University Compositions and methods for enhanced dendritic cell maturation and function
WO2007038720A2 (en) * 2005-09-27 2007-04-05 Coley Pharmaceutical Gmbh Modulation of tlr-mediated immune responses using adaptor oligonucleotides
US20080286819A1 (en) 2005-11-07 2008-11-20 Ravetch Jeffrey V Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof
AU2015349878A1 (en) 2014-11-21 2017-05-25 Bristol-Myers Squibb Company Antibodies against CD73 and uses thereof
WO2017087280A1 (en) * 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
KR20180134347A (ko) * 2016-04-15 2018-12-18 제넨테크, 인크. 암의 진단 및 치료 방법
CN109843327B (zh) * 2016-07-07 2022-05-13 小利兰·斯坦福大学托管委员会 抗体佐剂缀合物
US20180271996A1 (en) * 2017-02-28 2018-09-27 Mersana Therapeutics, Inc. Combination therapies of her2-targeted antibody-drug conjugates
CA3100544A1 (en) * 2018-05-17 2019-11-21 Bolt Biotherapeutics, Inc. Immunoconjugates
US20220152215A1 (en) * 2019-03-15 2022-05-19 Bolt Biotherapeutics, Inc. Immunoconjugates Targeting CEA
US20220143012A1 (en) * 2019-03-15 2022-05-12 Bolt Biotherapeutics, Inc. Macromolecule-Supported TLR Agonists
WO2020190725A1 (en) * 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
US20220226491A1 (en) * 2019-03-15 2022-07-21 Bolt Biotherapeutics, Inc. Immunoconjugates Targeting PD-L1
WO2020190731A1 (en) * 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2

Also Published As

Publication number Publication date
US20230165968A1 (en) 2023-06-01
JP2023519807A (ja) 2023-05-15
KR20220145871A (ko) 2022-10-31
AU2021226570A1 (en) 2022-09-29
EP4110403A1 (en) 2023-01-04
WO2021173832A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
CN114502592B (zh) 靶向cldn18.2的抗体及其制备方法和应用
US11400164B2 (en) Immunoconjugates targeting HER2
KR102679632B1 (ko) 신규한 항_cd137 항체 및 이의 용도
US20230165968A1 (en) Cancer treatment methods
TWI870335B (zh) 變異的嵌合4d5抗體及其與抗pd-1抗體聯合用於治療癌症的應用
EP4273170A1 (en) Pharmaceutical composition comprising anti-tigit antibody and anti-pd-1-anti-vegfa bispecific antibody, and use
JP7102670B2 (ja) 抗ｐｄ‐ｌ１抗体とｉｌ‐７との融合
EP3889172A1 (en) Targeted tgf beta inhibition
US20170151341A1 (en) Site specific her2 antibody drug conjugates
TWI884911B (zh) 具有改良之免疫療效但減弱之副作用之突變抗ctla-4抗體
KR20200124701A (ko) 항―ｐｄ－１ 항체 및 그의 용도
WO2021163989A1 (en) Anti-baff receptor antibodies and uses thereof
KR20200088810A (ko) 항―ｏｘ４０ 항체 및 그의 용도
US20220112258A1 (en) Bifunctional molecules with il-7 activity
CN117355331A (zh) 抗Siglec组合物及其用途
WO2024130003A1 (en) Cancer combination treatment method
US20260115307A1 (en) Anti-fucosyl-gm1 antibody drug conjugates
EP4725969A1 (en) Anti-her2 complementary bispecific antibody-drug conjugate, preparation method therefor and use thereof
WO2025038492A1 (en) Anti-ctla-4 antibodies and related binding molecules and methods and uses thereof
HK40100877A (en) Pharmaceutical composition comprising anti-tigit antibody and anti-pd-1-anti-vegfa bispecific antibody, and use
WO2026096695A1 (en) Anti-fucosyl-gm1 antibody drug conjugates
TW202539744A (zh) 抗ｃｅａｃａｍ５抗體藥物軛合物
TW202440158A (zh) 治療癌症患者之pd-1拮抗劑、lag3拮抗劑及結合191p4d12蛋白之抗體藥物結合物之組合療法
CN117715654A (zh) 包含抗-cd205抗体和免疫检查点抑制剂的药物组合
EA047699B1 (ru) Конъюгаты антитело-лекарственное средство, нацеленные на клаудин 18.2

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250826

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251027

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260202

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260423